{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:05:13Z","timestamp":1792670713194,"version":"4.5.0"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T00:00:00Z","timestamp":1571011200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Sustained virologic response (SVR) to interferon (IFN)\u2010free therapies ameliorates portal hypertension (PH); however, it remains unclear whether a decrease in hepatic venous pressure gradient (HVPG) after cure of hepatitis C translates into a clinical benefit. We assessed the impact of pretreatment HVPG, changes in HVPG, and posttreatment HVPG on the development of hepatic decompensation in patients with PH who achieved SVR to IFN\u2010free therapy. Moreover, we evaluated transient elastography (TE) and von Willebrand factor to platelet count ratio (VITRO) as noninvasive methods for monitoring the evolution of PH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Approach and Results<\/jats:title>\n                    <jats:p>\n                      The study comprised 90 patients with HVPG\u00a0\u2265\u00a06\u00a0mm\u00a0Hg who underwent paired HVPG, TE, and VITRO assessments before (baseline [BL]) and after (follow\u2010up [FU]) IFN\u2010free therapy. FU HVPG but not BL HVPG predicted hepatic decompensation (per mm\u00a0Hg, hazard ratio, 1.18; 95% confidence interval, 1.08\u20101.28;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u00a0&lt;\u00a00.001). Patients with BL HVPG\u00a0\u2264\u00a09\u00a0mm\u00a0Hg or patients who resolved clinically significant PH (CSPH) were protected from hepatic decompensation. In patients with CSPH, an HVPG decrease\u00a0\u2265\u00a010% was similarly protective (36\u00a0months, 2.5% vs. 40.5%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u00a0&lt;\u00a00.001) but was observed in a substantially higher proportion of patients (60% vs. 24%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u00a0&lt;\u00a00.001). Importantly, the performance of noninvasive methods such as TE\/VITRO for diagnosing an HVPG reduction\u00a0\u2265\u00a010% was inadequate for clinical use (area under the receiver operating characteristic curve [AUROC], \u00a0&lt;\u00a00.8), emphasizing the need for HVPG measurements. However, TE\/VITRO were able to rule in or rule out FU CSPH (AUROC, 0.86\u20100.92) in most patients, especially if assessed in a sequential manner.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Reassessment of HVPG after SVR improved prognostication in patients with pretreatment CSPH. An \u201cimmediate\u201d HVPG decrease\u00a0\u2265\u00a010% was observed in the majority of these patients and was associated with a clinical benefit, as it prevented hepatic decompensation. These results support the use of HVPG as a surrogate endpoint for interventions that lower portal pressure by decreasing intrahepatic resistance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hep.30885","type":"journal-article","created":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T16:59:52Z","timestamp":1564592392000},"page":"1023-1036","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":154,"title":["Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon\u2010Free Therapy"],"prefix":"10.1097","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2330-0017","authenticated-orcid":false,"given":"Mattias","family":"Mandorfer","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine III,Medical University of Vienna,Vienna,Austria"},{"name":"Vienna Hepatic Hemodynamic Lab,Medical University of Vienna,Vienna,Austria"},{"name":"Barcelona Hepatic Hemodynamic Lab, Liver Unit,Hospital Cl\u00ednic,Barcelona,Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Kozbial","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine III,Medical University of Vienna,Vienna,Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Schwabl","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine III,Medical University of Vienna,Vienna,Austria"},{"name":"Vienna Hepatic Hemodynamic Lab,Medical University of Vienna,Vienna,Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Chromy","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine III,Medical University of Vienna,Vienna,Austria"},{"name":"Vienna Hepatic Hemodynamic Lab,Medical University of Vienna,Vienna,Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Semmler","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine III,Medical University of Vienna,Vienna,Austria"},{"name":"Vienna Hepatic Hemodynamic Lab,Medical University of Vienna,Vienna,Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert F.","family":"St\u00e4ttermayer","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine III,Medical University of Vienna,Vienna,Austria"},{"name":"Vienna Hepatic Hemodynamic Lab,Medical University of Vienna,Vienna,Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Pinter","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine III,Medical University of Vienna,Vienna,Austria"},{"name":"Vienna Hepatic Hemodynamic Lab,Medical University of Vienna,Vienna,Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Hern\u00e1ndez\u2010Gea","sequence":"additional","affiliation":[{"name":"Barcelona Hepatic Hemodynamic Lab, Liver Unit,Hospital Cl\u00ednic,Barcelona,Spain"},{"name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS),Barcelona,Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd),Madrid,Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Fritzer\u2010Szekeres","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine,Medical University of Vienna,Vienna,Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Steindl\u2010Munda","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine III,Medical University of Vienna,Vienna,Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Trauner","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine III,Medical University of Vienna,Vienna,Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Peck\u2010Radosavljevic","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine III,Medical University of Vienna,Vienna,Austria"},{"name":"Vienna Hepatic Hemodynamic Lab,Medical University of Vienna,Vienna,Austria"},{"name":"Department of Internal Medicine and Gastroenterology (IMuG), Hepatology, Endocrinology, Rheumatology, and Nephrology with Centralized Emergency Service (ZAE),Klinikum Klagenfurt am W\u00f6rthersee,Klagenfurt,Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9032-4954","authenticated-orcid":false,"given":"Juan C.","family":"Garc\u00eda\u2010Pag\u00e1n","sequence":"additional","affiliation":[{"name":"Barcelona Hepatic Hemodynamic Lab, Liver Unit,Hospital Cl\u00ednic,Barcelona,Spain"},{"name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS),Barcelona,Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd),Madrid,Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2306-1992","authenticated-orcid":false,"given":"Peter","family":"Ferenci","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine III,Medical University of Vienna,Vienna,Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4590-3583","authenticated-orcid":false,"given":"Thomas","family":"Reiberger","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine III,Medical University of Vienna,Vienna,Austria"},{"name":"Vienna Hepatic Hemodynamic Lab,Medical University of Vienna,Vienna,Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,10,14]]},"reference":[{"key":"hep30885-bib-0001-20250501","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1097\/QAD.0000000000001020","article-title":"Interferon\u2010free treatment with sofosbuvir\/daclatasvir achieves sustained virologic response in 100% of HIV\/hepatitis C virus\u2010coinfected patients with advanced liver disease","volume":"30","year":"2016","journal-title":"AIDS"},{"key":"hep30885-bib-0002-20250501","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s12072-015-9691-4","article-title":"Advances in the management of HIV\/HCV coinfection","volume":"10","year":"2016","journal-title":"Hepatol Int"},{"key":"hep30885-bib-0003-20250501","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/apt.13315","article-title":"Interferon\u2010free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responses","volume":"42","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"hep30885-bib-0004-20250501","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.jhep.2015.06.003","article-title":"HCV targeting of patients with cirrhosis","volume":"63","year":"2015","journal-title":"J Hepatol"},{"key":"hep30885-bib-0005-20250501","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1053\/j.gastro.2017.03.018","article-title":"American Gastroenterological Association Institute Clinical Practice Update\u2010Expert Review: care of patients who have achieved a sustained virologic response after antiviral therapy for chronic hepatitis C infection","volume":"152","year":"2017","journal-title":"Gastroenterology"},{"key":"hep30885-bib-0006-20250501","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s11901-018-0405-y","article-title":"Portal hypertension reverses following successful antiviral treatment for HCV: fact or fiction?","volume":"17","year":"2018","journal-title":"Curr Hepatol Rep"},{"key":"hep30885-bib-0007-20250501","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1053\/j.gastro.2018.10.033","article-title":"What are the benefits of a sustained virologic response to direct\u2010acting antiviral therapy for hepatitis C virus infection?","volume":"156","year":"2019","journal-title":"Gastroenterology"},{"key":"hep30885-bib-0008-20250501","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jhep.2016.05.027","article-title":"Sustained virologic response to interferon\u2010free therapies ameliorates HCV\u2010induced portal hypertension","volume":"65","year":"2016","journal-title":"J Hepatol"},{"key":"hep30885-bib-0009-20250501","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/apt.13844","article-title":"Interferon\u2010free regimens improve portal hypertension and histological necroinflammation in HIV\/HCV patients with advanced liver disease","volume":"45","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"hep30885-bib-0010-20250501","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1053\/j.gastro.2017.07.016","article-title":"Effects of all\u2010oral anti\u2010viral therapy on HVPG and systemic hemodynamics in patients with hepatitis C virus\u2010associated cirrhosis","volume":"153","year":"2017","journal-title":"Gastroenterology"},{"key":"hep30885-bib-0011-20250501","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/jvh.12706","article-title":"Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension","volume":"24","year":"2017","journal-title":"J Viral Hepat"},{"key":"hep30885-bib-0012-20250501","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrgastro.2009.149","article-title":"The clinical use of HVPG measurements in chronic liver disease","volume":"6","year":"2009","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"hep30885-bib-0013-20250501","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","article-title":"Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension","volume":"63","year":"2015","journal-title":"J Hepatol"},{"key":"hep30885-bib-0014-20250501","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00508-017-1262-3","article-title":"Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III)","volume":"129","year":"2017","journal-title":"Wien Klin Wochenschr"},{"key":"hep30885-bib-0015-20250501","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s11901-019-00469-x","article-title":"Hepatic venous pressure gradient\u2010response in non\u2010selective beta\u2010blocker treatment \u2013 is it worth measuring?","volume":"18","year":"2019","journal-title":"Curr Hepatol Rep"},{"key":"hep30885-bib-0016-20250501","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1053\/gast.1996.v111.pm8780575","article-title":"Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10\u2010year prospective study","volume":"111","year":"1996","journal-title":"Gastroenterology"},{"key":"hep30885-bib-0017-20250501","article-title":"The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials","year":"2019","journal-title":"Hepatology"},{"key":"hep30885-bib-0018-20250501","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.dld.2016.09.013","article-title":"Beta blockers and cirrhosis, 2016","volume":"49","year":"2017","journal-title":"Dig Liver Dis"},{"key":"hep30885-bib-0019-20250501","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jhep.2016.11.001","article-title":"Beta adrenergic blockade and decompensated cirrhosis","volume":"66","year":"2017","journal-title":"J Hepatol"},{"key":"hep30885-bib-0020-20250501","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/hep.30314","article-title":"Prioritization of therapeutic targets and trial design in cirrhotic portal hypertension","volume":"69","year":"2019","journal-title":"Hepatology"},{"key":"hep30885-bib-0021-20250501","doi-asserted-by":"crossref","first-page":"1756284818811294","DOI":"10.1177\/1756284818811294","article-title":"Advances in therapeutic options for portal hypertension","volume":"11","year":"2018","journal-title":"Therap Adv Gastroenterol"},{"key":"hep30885-bib-0022-20250501","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/apt.14522","article-title":"Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity","volume":"47","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"hep30885-bib-0023-20250501","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/apt.12564","article-title":"Von Willebrand Factor as a new marker for non\u2010invasive assessment of liver fibrosis and cirrhosis in patients with chronic hepatitis C","volume":"39","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"hep30885-bib-0024-20250501","article-title":"The VITRO score (Von Willebrand factor antigen\/thrombocyte ratio) as a new marker for clinically significant portal hypertension in comparison to other non\u2010invasive parameters of fibrosis including ELF test","volume":"11","year":"2016","journal-title":"PLoS One"},{"key":"hep30885-bib-0025-20250501","first-page":"320","article-title":"S3 guideline hepatitis C addendum","volume":"53","year":"2015","journal-title":"Z Gastroenterol"},{"key":"hep30885-bib-0026-20250501","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1055\/a-0599-1320","article-title":"Prophylaxis, diagnosis and therapy of hepatitis\u2010C\u2010virus (HCV) infection: the German guidelines on the management of HCV infection \u2010 AWMF\u2010Register\u2010No.: 021\/012","volume":"56","year":"2018","journal-title":"Z Gastroenterol"},{"key":"hep30885-bib-0027-20250501","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","article-title":"EASL recommendations on treatment of hepatitis C 2015","volume":"63","year":"2015","journal-title":"J Hepatol"},{"key":"hep30885-bib-0028-20250501","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","article-title":"EASL recommendations on treatment of hepatitis C 2016","volume":"66","year":"2017","journal-title":"J Hepatol"},{"key":"hep30885-bib-0029-20250501","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL recommendations on treatment of hepatitis C 2018","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"hep30885-bib-0030-20250501","article-title":"Measurement of the hepatic venous pressure gradient and transjugular liver biopsy","journal-title":"J Vis Exp"},{"key":"hep30885-bib-0031-20250501","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jhep.2017.10.020","article-title":"Clinical states of cirrhosis and competing risks","volume":"68","year":"2018","journal-title":"J Hepatol"},{"key":"hep30885-bib-0032-20250501","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/j.gastro.2007.05.024","article-title":"Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis","volume":"133","year":"2007","journal-title":"Gastroenterology"},{"key":"hep30885-bib-0033-20250501","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/hep.24418","article-title":"Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis","volume":"54","year":"2011","journal-title":"Hepatology"},{"key":"hep30885-bib-0034-20250501","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/liv.13943","article-title":"Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease","volume":"39","year":"2019","journal-title":"Liver Int"},{"key":"hep30885-bib-0035-20250501","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jhep.2009.05.031","article-title":"Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg\u2010negative chronic hepatitis B and significant portal hypertension","volume":"51","year":"2009","journal-title":"J Hepatol"},{"key":"hep30885-bib-0036-20250501","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/j.gastro.2018.07.006","article-title":"Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis","volume":"155","year":"2018","journal-title":"Gastroenterology"},{"key":"hep30885-bib-0037-20250501","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/j.cgh.2015.04.013","article-title":"Association between severe portal hypertension and risk of liver decompensation in patients with hepatitis C, regardless of response to antiviral therapy","volume":"13","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep30885-bib-0038-20250501","first-page":"97A","article-title":"Dynamic prediction of the risk of decompensation\/death in patients with compensated cirrhosis based on serial hepatic venous pressure gradient (HVPG) measurements","volume":"68","year":"2018","journal-title":"Hepatology"},{"key":"hep30885-bib-0039-20250501","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s11901-019-00461-5","article-title":"HVPG measurements as a surrogate of clinical events in cirrhosis: experience from clinical trials","volume":"18","year":"2019","journal-title":"Curr Hepatol Rep"},{"key":"hep30885-bib-0040-20250501","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/liv.12522","article-title":"A prospective observational study on tolerance and satisfaction to hepatic haemodynamic procedures","volume":"35","year":"2015","journal-title":"Liver Int"},{"key":"hep30885-bib-0041-20250501","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00535-011-0517-4","article-title":"Non\u2010selective beta\u2010blockers improve the correlation of liver stiffness and portal pressure in advanced cirrhosis","volume":"47","year":"2012","journal-title":"J Gastroenterol"},{"key":"hep30885-bib-0042-20250501","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1136\/gut.2010.235689","article-title":"Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension","volume":"60","year":"2011","journal-title":"Gut"},{"key":"hep30885-bib-0043-20250501","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1053\/j.gastro.2018.11.053","article-title":"Validation of Baveno VI criteria for screening and surveillance of esophageal varices in patients with compensated cirrhosis and a sustained response to antiviral therapy","volume":"156","year":"2019","journal-title":"Gastroenterology"},{"key":"hep30885-bib-0044-20250501","first-page":"412","article-title":"Non\u2010invasive response prediction in prophylactic carvedilol therapy for cirrhotic patients with esophageal varices","volume":"70","year":"2018","journal-title":"J Hepatol"},{"key":"hep30885-bib-0045-20250501","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jhep.2012.12.011","article-title":"Non\u2010selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL\u20106 in patients with cirrhosis","volume":"58","year":"2013","journal-title":"J Hepatol"},{"key":"hep30885-bib-0046-20250501","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1053\/j.gastro.2019.03.021","article-title":"Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis","volume":"157","year":"2019","journal-title":"Gastroenterology"},{"key":"hep30885-bib-0047-20250501","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.jhep.2009.01.014","article-title":"Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis","volume":"50","year":"2009","journal-title":"J Hepatol"},{"key":"hep30885-bib-0048-20250501","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL\u2010EASD\u2010EASO Clinical Practice Guidelines for the management of non\u2010alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J Hepatol"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.30885","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep.30885","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep.30885","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.30885","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T16:01:41Z","timestamp":1746115301000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.30885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,14]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.30885","relation":{},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,14]]},"assertion":[{"value":"2019-05-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}